Alzheimer's disease cerebrospinal fluid biomarker discovery: A proteomics approach

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 6, 2005, Pages 557-564

  D'Ascenzo, Mark ^a   Relkin, Norman R ^b   Lee, Kelvin H ^a  

^a Cornell University   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Alzheimer's disease; Biomarker; Cerebrospinal fluid; iTRAQ; Proteomics

Indexed keywords

BIOLOGICAL MARKER; HAPTOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PROTEOME; SERUM ALBUMIN; TRANSFERRIN; TRYPSIN INHIBITOR;

ALZHEIMER DISEASE; ANTIBODY AFFINITY; BLOOD BRAIN BARRIER; CAPILLARY ELECTROPHORESIS; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; DIFFERENTIAL DIAGNOSIS; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SEPARATION TECHNIQUE; SOLID PHASE EXTRACTION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CEREBROSPINAL FLUID; ELECTROPHORESIS, CAPILLARY; HUMANS; PROTEOMICS;

ESCHERICHIA COLI;

EID: 28844447842     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Leifer BP: Early diagnosis of Alzheimer's disease: Clinical and economic benefits. J Am Geriatr Soc (2003) 51(5 Suppl):S281-S288.
2. Ho L, Sharma N, Blackman L, Festa E, Reddy G, Pasinetti GM: From proteomics to biomarker discovery in Alzheimer's disease. Brain Res Brain Res Rev (2005) 48(2):360-369.
3. American Psychiatric Association: Task Force on DSM-IV. In: Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. American Psychiatric Association, Washington, DC, USA (2000).
4. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 34(7):939-944.
5. Zamrini E, De Santi S, Toler M: Imaging is superior to cognitive testing for early diagnosis of Alzheimer's disease. Neurobiol Aging (2004) 25(5):685-691.
6. Frisoni GB: Structural imaging in the clinical diagnosis of Alzheimer's disease: Problems and tools. J Neurol Neurosurg Psychiatry (2001) 70(6):711-718.
7. Baker M: In biomarkers we trust? Nat Biotechnol (2005) 23(3):297-304.
8. Andreasen N, Blennow K: CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg (2005) 107(3):165-173.
9. Romeo MJ, Espina V, Lowenthal M, Espina BH, Petricoin EF 3rd, Liotta LA: CSF proteome: A protein repository for potential biomarker identification. Expert Rev Proteomics (2005) 2(1):57-70.
10. Reiber H: Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta (2001) 310(2):173-186.
11. Sickmann A, Dormeyer W, Wortelkamp S, Woitalla D, Kuhn W, Meyer HE: Towards a high resolution separation of human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 771(1-2):167-196.
12. Maccarrone G, Birg I, Malisch E, Rosenhagen MC, Ditzen C, Chakel JA, Mandel F, Reimann A, Doertbudak C-C, Haegler K, Holsboer F, Turck CW: In-depth analysis of the human CSF proteome using protein prefractionation. Clinical Proteomics (2004) 1 (3-4):333-364.
13. Maccarrone G, Milfay D, Birg I, Rosenhagen M, Holsboer F, Grimm R, Bailey J, Zolotarjova N, Turck CW: Mining the human cerebrospinal fluid proteome by immunodepletion and shotgun mass spectrometry. Electrophoresis (2004) 25(14):2402-2412.
14. Wenner BR, Lovell MA, Lynn BC: Proteomic analysis of human ventricular cerebrospinal fluid from neurologically normal, elderly subjects using two-dimensional LC-MS/MS. J Proteome Res (2004) 3(1):97-103.
15. Ogata Y, Charlesworth MC, Muddiman DC: Evaluation of protein depletion methods for the analysis of total-, phospho- and glycoproteins in lumbar cerebrospinal fluid. J Proteome Res (2005) 4(3):837-845.
16. Raymackers J, Daniels A, De Brabandere V, Missiaen C, Dauwe M, Verhaert P, Vanmechelen E, Meheus L: Identification of two-dimensionally separated human cerebrospinal fluid proteins by N-terminal sequencing, matrix-assisted laser desorption/Ionisation - mass spectrometry, nanoliquid chromatography-electrospray ionization-time of flight-mass spectrometry, and tandem mass spectrometry. Electrophoresis (2000) 21(11):2266-2283.
17. Yuan X, Desiderio DM: Proteomics analysis of prefractionated human lumbar cerebrospinal fluid. Proteomics (2005) 5(2):541-550.
18. O'Farrell PH: High resolution two-dimensional electrophoresis of proteins. J Biol Chem (1975) 250(10):4007-4021.
19. Garbis S, Lubec G, Fountoulakis M: Limitations of current proteomics technologies. J Chromatogr A (2005) 1077(1):1-18.
20. Choe LH, Dutt MJ, Relkin N, Lee KH: Studies of potential cerebrospinall fluid molecular markers for Alzheimer's disease. Electrophoresis (2002) 23(14):2247-2251.
21. Finehout EJ, Franck Z, Lee KH: Towards two-dimensional electrophoresis mapping of the cerebrospinal fluid proteome from a single individual. Electrophoresis (2004) 25(15):2564-2575.
22. Lescuyer P, Allard L, Zimmermann-Ivol CG, Burgess JA, Hughes-Frutiger S, Burkhard PR, Sanchez JC, Hochstrasser DF: Identification of post-mortem cerebrospinal fluid proteins as potential biomarkers of ischemia and neurodegeneration. Proteomics (2004) 4(8):9934-2241.
23. Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG: The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med (1996) 335(13):924-930.
24. Lee KH, Harrington MG: Premortem diagnosis of Creutzfeldt-Jakob disease by cerebrospinal fluid analysis. Lancet (1996) 348(9031):887.
25. Davidsson P, Folkesson S, Christiansson M, Lindbjer M, Dellheden B, Blennow K, Westman-Brinkmalm A: Identification of proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/isonisation mass spectrometry. Rapid Commun Mass Spectrom (2002) 16(22):2083-2088.
26. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P: Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res (2003) 118(1-2):140-146.
27. Sihlbom C, Davidsson P, Emmett MR, Marshall AG, Nilsson CL: Glycoproteomics of cerebrospinal fluid in neurodegenerative disease. Int J Mass Spectrom (2004) 234(1-3):145-152.
28. Hakansson K, Emmett MR, Marshall AG, Davidsson P, Nilsson CL: Structural analysis of 2D-gel-separated glycoproteins from human cerebrospinal fluid by tandem high-resolution mass spectrometry. J Proteome Res (2003) 2(6):581-588.
29. Wittke S, Mischak H, Walden M, Kolch W, Radler T, Wiedemann K Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: Towards new diagnostic and therapeutic approaches. Electrophoresis (2005) 26(7-8):1476-1487.
30. Theodorescu D, Fliser D, Wittke S, Mischak H, Krebs R, Walden M, Ross M, Eltze E, Bettendorf O, Wulfing C, Semjonow A: Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis (2005) 26(14):2797-2808.
31. Sassi AP, Andel F 3rd, Bitter HM, Brown MP, Chapman RG, Espiritu J, Greenquist AC, Guyon I, Horchi-Alegre M, Stults KL, Wainright A: An automated, sheathless capillary electrophoresis-mass spectrometry platform for discovery of biomarkers in human serum. Electrophoresis (2005) 26(7-8):1500-1512.
32. Chamrad D, Meyer HE: Valid data from large-scale proteomics studies. Nat Methods (2005) 2(9):647-648.
33. Finehout EJ, Lee KH: An introduction to mass spectrometry applications in biological research. Biochem Mol Biol Education (2004) 32(2):93-100.
34. Swanson SK, Washburn MP: The continuing evolution of shotgun proteomics. Drug Discov Today (2005) 10(10):719-725.
35. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S: Multiplexed protein quantitation in Saccharomyces; cerevisise using amine-reactive isobaric tagging reagents. Mol Cell Proteomics (2004) 3(12):1154-1169.
36. Gygl SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R: Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol (1999) 17(10):994-999.
37. Zhang J, Goodlett DR, Peskind ER, Quinn JF, Zhou Y, Wang Q, Pan C, Yi E, Eng J, Aebersold RH, Montine TJ: Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging (2005) 26(2):207-227.
38. Zhang J, Goodlett DR, Quinn JF, Peskind E, Kaye JA, Zhou Y, Pan C, Yi E, Eng J, Wang Q, Aebersold RH, Montine TJ: Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis (2005) 7(2):125-133.
39. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, Hochstrasser DF, Sanchez JC: A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics (2003) 3(8):1486-1494.
40. Aggarwal K, Choe LH, Lee KH: Quantitative analysis of protein expression using amine-specific isobaric tags in Escherichia coli cells expressing rhsA elements. Proteomics (2005) 5(9):2297-2308.
41. Choe LH, Aggarwal K, Franck Z, Lee KH: A comparison of the consistency of proteome quantitation using two-dimensional electrophoresis and shotgun isobaric tagging in Escherichia coli cells. Electrophoresis (2005) 26(12):2437-2449.
42. Lewczuk P, Esselmann H, Groemer TW, Bibl M, Maier JM, Steinacker P, Otto M, Kornhuber J, Wiltfang J: Amyloid β peptides in scerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: Evidence of novel biomarkers in Alzheimer's disease. Biol Psychiatry (2004) 55(5):524-530.
43. Sanchez JC, Guillaume E, Lescuyer P, Allard L, Carrette O, Scherl A, Burgess J, Corthals GL, Burkhard PR, Hochstrasser DF: Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics (2004) 4(8):2229-2233.